The CDMO says the pending acquisition of two U.S. drug substance facilities, slated to close in the second or third quarter, positions it for sustained profitable growth.
The platform is designed to help biologics developers accelerate time to clinic, while supporting scalability and regulatory compliance, according to the company.
